Skip to main content
Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. — Investor Relations & Filings

Ticker · CANF ISIN · IL0010944739 LEI · 549300ZLRH6GSBOHFZ59 TA Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country IL Israel
Listing TA CANF

About Can-Fite BioPharma Ltd.

https://www.canfite.com/

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.

Recent filings

Filing Released Lang Actions
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Regulatory Filings
2026-04-30 English
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Regulatory Filings
2026-04-30 English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
Foreign Filer Report
2026-04-30 English
Immediate Report of Meeting to be held on ON MAY 28, 2026, proxy statement
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form 6-K filed by a foreign private issuer (Can-Fite BioPharma Ltd.) announcing its Annual General Meeting and furnishing the Notice and Proxy Statement, Proxy Card and Voting Instruction Card (Exhibits 99.1–99.3). These exhibits constitute proxy solicitation materials sent to shareholders to request their votes at the AGM. Under the filing definitions, such materials are classified as a Proxy Solicitation & Information Statement (PSI).
2026-04-24 English
Immediate Report of Meeting to be held on ON MAY 28, 2026, proxy statement
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form 6-K filing by a foreign private issuer providing the Notice of 2026 Annual General Meeting of Shareholders, the proxy statement, proxy card, and voting instruction card. It is pre-meeting solicitation material sent to shareholders requesting votes and providing meeting details. This corresponds to the Proxy Solicitation & Information Statement category (PSI).
2026-04-24 English
Immediate Report of Meeting to be held on ON MAY 28, 2026, proxy statement
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an official convening notice for the company’s annual general meeting, detailing the date, time, location, agenda items, voting procedures, and proxies for shareholder votes. It is sent to shareholders to provide information on proposed resolutions and to solicit their votes. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.